February 05, 2024
On Jan. 25, 2024, Azurity Pharmaceuticals announced the recall of one lot of the stimulant medication Zenzedi® (dextroamphetamine sulfate tablets) 30mg to the consumer level after one bottle was found to contain the antihistamine carbinoxamine maleate. Zenzedi is approved for treating attention deficit hyperactivity disorder (ADHD) and narcolepsy. Patients who take carbinoxamine instead of Zenzedi could experience undertreatment of their disease symptoms. In addition, adverse effects from taking the antihistamine carbinoxamine maleate can include drowsiness and central nervous system depression. The FDA notice is here.
Last updated: February 05, 2024